dsm-firmenich Press Release dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025 Kaiseraugst (Switzerland), Maastricht (Netherlands), May 6, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announces that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting today, including the Management Report, the consolidated financial statements as well as the Sustainability Report 2024. Key highlights include: Thomas Leysen was re-elected and confirmed as Chairman of the Board. Patrick Firmenich, Sze Cotte-Tan, Antoine Firmenich, Erica Mann, Carla Mahieu, Frits van Paasschen, André Pometta, John Ramsay, Richard Ridinger, and Corien Wortmann were re-elected to the board. Shareholders approved the dividend of €2.50 per share. The dividend will be paid as of May 16, 2025, and the last trading day with entitlement to receive the payment is May 7, 2025. Shareholders approved a maximum total amount of remuneration of €3,682,582 for the Board of Directors for the year through the 2026 AGM. Shareholders approved a maximum total amount of remuneration of €43,982,072 for the Executive Committee for the financial year 2026. Shareholders also endorsed the 2024 Compensation Report in a consultative vote. Carla Mahieu, Thomas Leysen, Frits van Paasschen, and André Pometta were re-elected to the Compensation Committee. The Board intends to appoint Carla Mahieu as Chair of the committee. PricewaterhouseCoopers AG was elected as auditor. Christian Hochstrasser was re-elected as the independent proxy. An amendment to the capital band provision in the Articles of Association allowing the Board of Directors to decrease the share capital one or several times within the limit of 90% of the current share capital. This authorization will be used to reduce the capital following the implementation of dsm-firmenich’s share buyback program announced on February 13, 2025. The shareholders in attendance, together with the votes represented by independent proxy, represented 72.72% of shares. PDF version of this press release can be found here. About dsm-firmenich As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss company with dual headquarters in Kaiseraugst, Switzerland and Maastricht, Netherlands, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com Story Continues For more information Media relations Robin Roothans tel. +41 (0)79 280 03 96 e-mail [email protected] Investor relations Dave Huizing tel. +31 (0)88 425 7306 e-mail [email protected] Forward-looking statements This press release may contain forward-looking statements with respect to dsm-firmenich’s future performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions. Attachment Press release_dsm shareholders approve all resolutions at Annual General Meeting 2025_20250506_FINAL View Comments
dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...